Vor Biopharma Inc. 8-K

What Happened Vor Biopharma Inc. announced on March 26–27, 2026 that it entered into a Securities Purchase Agreement to sell 5,338,078 shares of common stock in a private placement to investors affiliated with TCGX at $14.05 per share for gross proceeds of approximately $75.0 million. The closing is expected on March 30, 2026, subject to customary closing conditions. The company also entered into a Registration Rights Agreement and issued a press release on March 27, 2026 announcing the transaction.

Key Details

• Shares offered: 5,338,078 common shares at $14.05 per share; gross proceeds ≈ $75.0 million.
• Expected closing date: March 30, 2026 (subject to customary closing conditions).
• Pro forma shares outstanding after closing: 54,185,582 common shares.
• Registration commitments: file a Form S-3 within 30 days of closing and use best efforts to have it effective within 60 days (subject to extensions); liquidated damages may apply if deadlines are missed.
• Use of proceeds: to advance development of Vor’s clinical pipeline and for general corporate purposes.

Why It Matters This financing provides Vor Biopharma with near-term capital to support its clinical programs and corporate needs, reducing immediate funding uncertainty. However, the issuance increases the company’s share count (dilution to existing shareholders) and the transaction is subject to closing conditions so it is not final until closing. The registration rights mean the new investor shares are expected to be registered for resale shortly after closing, which can affect share liquidity and future trading supply.